These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
99 related articles for article (PubMed ID: 10025882)
1. Decreased HER-2 tyrosine kinase expression in rectal mucosa of FAP patients following low-dose sulindac chemoprevention. Winde G; Lügering N; Glodny B; Schmid KW; Müller O; Senninger N; Osswald H Cancer Lett; 1998 Dec; 134(2):201-7. PubMed ID: 10025882 [TBL] [Abstract][Full Text] [Related]
2. Prostaglandin levels in human colorectal mucosa: effects of sulindac in patients with familial adenomatous polyposis. Giardiello FM; Spannhake EW; DuBois RN; Hylind LM; Robinson CR; Hubbard WC; Hamilton SR; Yang VW Dig Dis Sci; 1998 Feb; 43(2):311-6. PubMed ID: 9512123 [TBL] [Abstract][Full Text] [Related]
3. Clinical and genomic influence of sulindac on rectal mucosa in familial adenomatous polyposis. Winde G; Schmid KW; Brandt B; Müller O; Osswald H Dis Colon Rectum; 1997 Oct; 40(10):1156-68; discussion 1168-9. PubMed ID: 9336110 [TBL] [Abstract][Full Text] [Related]
4. Complete reversion and prevention of rectal adenomas in colectomized patients with familial adenomatous polyposis by rectal low-dose sulindac maintenance treatment. Advantages of a low-dose nonsteroidal anti-inflammatory drug regimen in reversing adenomas exceeding 33 months. Winde G; Schmid KW; Schlegel W; Fischer R; Osswald H; Bünte H Dis Colon Rectum; 1995 Aug; 38(8):813-30. PubMed ID: 7634976 [TBL] [Abstract][Full Text] [Related]
5. Long-term treatment with sulindac in familial adenomatous polyposis: a prospective cohort study. Cruz-Correa M; Hylind LM; Romans KE; Booker SV; Giardiello FM Gastroenterology; 2002 Mar; 122(3):641-5. PubMed ID: 11874996 [TBL] [Abstract][Full Text] [Related]
6. Rectal epithelial apoptosis in familial adenomatous polyposis patients treated with sulindac. Keller JJ; Offerhaus GJ; Polak M; Goodman SN; Zahurak ML; Hylind LM; Hamilton SR; Giardiello FM Gut; 1999 Dec; 45(6):822-8. PubMed ID: 10562579 [TBL] [Abstract][Full Text] [Related]
7. Efficacy and safety of eflornithine (CPP-1X)/sulindac combination therapy versus each as monotherapy in patients with familial adenomatous polyposis (FAP): design and rationale of a randomized, double-blind, Phase III trial. Burke CA; Dekker E; Samadder NJ; Stoffel E; Cohen A BMC Gastroenterol; 2016 Aug; 16(1):87. PubMed ID: 27480131 [TBL] [Abstract][Full Text] [Related]
8. Combination of Sulindac and Bexarotene for Prevention of Intestinal Carcinogenesis in Familial Adenomatous Polyposis. Bowen CM; Walter L; Borras E; Wu W; Ozcan Z; Chang K; Bommi PV; Taggart MW; Thirumurthi S; Lynch PM; Reyes-Uribe L; Scheet PA; Sinha KM; Vilar E Cancer Prev Res (Phila); 2021 Sep; 14(9):851-862. PubMed ID: 34266857 [TBL] [Abstract][Full Text] [Related]
9. Tissue prostanoids as biomarkers for chemoprevention of colorectal neoplasia: correlation between prostanoid synthesis and clinical response in familial adenomatous polyposis. Yang VW; Geiman DE; Hubbard WC; Spannhake EW; Hylind LM; Hamilton SR; Giardiello FM Prostaglandins Other Lipid Mediat; 2000 Jan; 60(1-3):83-96. PubMed ID: 10680778 [TBL] [Abstract][Full Text] [Related]